Catalyst Pharmaceutical Inc. (CPRX) Stock Price

CPRXStock
$31.4917.44%52W
Market Cap$3.85B
P/E17.99x
PEG Ratio0.92
Div yield
Beta-0.29

CPRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)30.78%
Price vs S&P 500 (4W)0.78%
PEG Ratio0.92
VGM Score61.94
P/E Ratio (Annual)17.99x

CPRX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q1 2026$0.64$0.79+22.91%(+$0.15)
Q4 2025$0.50$0.68+35.70%(+$0.18)
Q3 2025$0.54$0.68+26.34%(+$0.14)
Q2 2025$0.54$0.68+25.01%(+$0.14)

CPRX Analyst Recommendations

Apr 2026
May 2026
Jun 2026
Jul 2026
4.43
4.43
3.67
2.44

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CPRXCatalyst Pharmaceutical Inc.
CBB$31.49
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Catalyst Pharmaceutical Inc.

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company commercializes three FDA-approved drugs: FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). It pursues growth through acquiring accretive assets, including clinical-stage candidates with established proof of concept.